CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Blueprint Medicines Corporation - BPMC CFD

92.93
1.78%
Market Trading Hours* (UTC) Open now
Closes on Thursday at 21:00

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.23
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024318 %
Charges from full value of position ($-0.24)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
-0.024318%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.002096 %
Charges from full value of position ($0.02)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
0.002096%
Overnight fee time 22:00 (UTC)
Min traded quantity 0.1
Currency USD
Margin 50.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 94.32
Open 93.97
1-Year Change 16.23%
Day's Range 92.55 - 94.55
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 11, 2024 94.32 -0.17 -0.18% 94.49 96.39 93.07
Dec 10, 2024 95.14 0.97 1.03% 94.17 97.23 94.17
Dec 9, 2024 94.36 -0.54 -0.57% 94.90 96.70 91.58
Dec 6, 2024 95.81 1.77 1.88% 94.04 96.89 93.22
Dec 5, 2024 94.59 0.02 0.02% 94.57 96.15 93.48
Dec 4, 2024 96.11 3.30 3.56% 92.81 98.39 92.65
Dec 3, 2024 96.37 1.88 1.99% 94.49 96.75 94.49
Dec 2, 2024 97.13 1.53 1.60% 95.60 97.88 95.01
Nov 29, 2024 95.86 1.38 1.46% 94.48 97.84 94.35
Nov 27, 2024 94.97 0.21 0.22% 94.76 95.34 92.16
Nov 26, 2024 94.21 2.11 2.29% 92.10 95.11 91.48
Nov 25, 2024 93.73 0.40 0.43% 93.33 95.75 92.76
Nov 22, 2024 94.08 -0.57 -0.60% 94.65 98.13 93.54
Nov 21, 2024 96.56 1.83 1.93% 94.73 97.98 91.62
Nov 20, 2024 94.70 0.53 0.56% 94.17 94.91 91.69
Nov 19, 2024 94.51 6.88 7.85% 87.63 95.15 87.63
Nov 18, 2024 90.14 1.84 2.08% 88.30 90.45 87.44
Nov 15, 2024 88.64 -3.12 -3.40% 91.76 95.09 88.07
Nov 14, 2024 95.43 0.30 0.32% 95.13 97.95 95.07
Nov 13, 2024 96.52 -0.19 -0.20% 96.71 100.04 96.37

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
Leverage
2:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Blueprint Medicines Corporation Company profile

About Blueprint Medicines Corp

Blueprint Medicines Corporation is a global precision therapy company that is inventing medicines for people with cancer and blood disorders. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib) to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include BLU-263 (KIT), AYVAKIT (avapritinib) (PDGFRA), BLU-701 (EGFR), BLU-945 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing and commercializing avapritinib for the treatment of advanced SM, and developing avapritinib for the treatment of non-advanced SM. The Company is developing BLU-263, an investigational, orally available KIT inhibitor, for the treatment of non-advanced SM and other mast cell disorders.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Blueprint Medicines Corp revenues decreased 77% to $180.1M. Net loss totaled $644.1M vs. income of $313.9M. Revenues reflect Collaboration revenue decrease of 84% to $122.4M. Net loss reflects Other Research and development increase of 91% to $561.4M (expense), Selling/General/Admin Expense increase of 24% to $143.3M (expense), Stock-based Compensation in SGA increase of 24% to $52M (expense).

Industry: Biotechnology & Medical Research (NEC)

45 Sidney Street
CAMBRIDGE
MASSACHUSETTS 02139
US

People also watch

ETH/USD

3,937.93 Price
+2.770% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

XRP/USD

2.41 Price
-1.040% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01200

BTC/USD

101,383.35 Price
-0.210% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

Gold

2,682.27 Price
-1.310% 1D Chg, %
Long position overnight fee -0.0160%
Short position overnight fee 0.0078%
Overnight fee time 22:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading